H.C. Wainwright lowered the firm’s price target on BioAtla to $17 from $20 and keeps a Buy rating on the shares post the Q4 results. BioAtla had approximately $216M in cash and cash equivalents, which is sufficient to support operations into 2025, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCAB:
- BioAtla reports Q4 net loss $27.5M vs. net loss of $23.4M last year
- BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call
- BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
- BioAtla president Scott Smith departs
